|
|
|
|
|
What To Expect From the 2023 European Society of Medical Oncology Annual Meeting |
|
|
|
|
|
| Proffered Paper Session - Genitourinary Tumors, Prostate - 10:00 - 11:30 AM EST
|
|
|
|
|
1764O - Timing of Radiotherapy After Radical Prostatectomy: Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]
Presented By: Noel Clarke, MBBS, FRCS, ChM
|
|
|
|
|
1765O - Interim Results From a Phase 1 Study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients With Metastatic Castration-Resistant Prostate Cancer
Presented By: William Kelly, DO
|
|
|
|
|
LBA84 - Enzalutamide and 177Lu-PSMA-617 in Poor-Risk, Metastatic, Castration-Resistant Prostate Cancer: A Randomised, Phase 2 Trial: ENZA-P (ANZUP 1901)
Presented By: Louise Emmett, MBChB, FRACP, MD
|
|
|
|
|
1770O - Refining Risk Stratification in Patients Undergoing Radiotherapy and Long-Term ADT for High-Risk/locally Advanced Prostate Cancer: An Individual Patient Data Analysis of Randomized Controlled Trials from the ICECaP Consortium
Presented By: Praful Ravi, MB, BChir, MRCP
|
|
|
|
|
|
|
| Proffered Paper Session 1 - Genitourinary Tumors, Non-Prostate 2:30 - 4:00 AM EST
|
|
|
|
|
LBA102 - THOR-2 Cohort 1: Results of Erdafitinib vs Intravesical Chemotherapy in Patients with High-Risk Nonmuscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Who Received Prior Bacillus Calmette-Guérin Treatment
Presented By: James Catto, MB ChB FRCS(urol) PhD FRSB
2360O - the Double Antibody Drug Conjugate Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma
Presented By: Bradley A. McGregor, MD
|
|
|
|
|
|
|
|
|
|
LBA103 - ICRA: Efficacy of Paclitaxel with Tremelimumab +/- Durvalumab in Metastatic Urothelial Carcinoma After Progression on Platinum Chemotherapy and Anti-PD-(L)1
Presented By: Sarah M.H. Einerhand, MD
|
|
|
|
|
| Proffered Paper Session 2 - Genitourinary Tumors, Non-Prostate 8:45 - 10:15 AM EST
|
|
|
|
|
LBA87 - Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Presented By: Toni Choueiri , MD
|
|
|
|
|
LBA88 - Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3 LITESPARK-005 Study
Presented By: Laurence Albiges, MD, Ph.D.
|
|
|
|
|
1881O - Safety and Efficacy of Two Doses of Belzutifan in Patients With Advanced RCC: Results of the Randomized Phase 2 LITESPARK-013 Study
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
|
|
| Mini Oral Session - Genitourinary Tumors, Prostate 2:30 - 3:35 AM EST
|
|
|
|
|
1771MO - Pembrolizumab plus Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer: Randomized Double-Blind Phase 3 KEYNOTE-641 Study
Presented By: Julie Graff, MD
|
|
|
|
|
1772MO - Pembrolizumab plus Enzalutamide and Androgen Deprivation Therapy for Patients with Metastatic Hormone-Sensitive Prostate Cancer: Randomized Double-Blind Phase 3 KEYNOTE-991 Study
Presented By: Christian Gratzke, MD
|
|
|
|
|
LBA85 - Niraparib with Abiraterone Acetate plus Prednisone as First-Line Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: Three-Year Update and Final Analysis of MAGNITUDE
Presented By: Kim Chi MD, FRCPC
|
|
|
|
|
LBA86 - Androgen Receptor Pathway Inhibitors or Taxanes for Patients with Metastatic Castration-Resistant Prostate Cancer: A Direct Comparison in ProBio, a Randomized, Outcome-Adaptive, Biomarker-Driven Platform Trial
Presented By: Henrik Grönberg, MD
|
|
|
|
|
| Mini Oral Session - Genitourinary Tumors, Non-Prostate 4:15 - 5:45 AM EST
|
|
|
|
|
LBA104 - First Safety and Efficacy Results of the TAR-210 Erdafitinib Intravesical Delivery System in Patients with Nonmuscle-Invasive Bladder Cancer with Select FGFR Alterations
Presented By: Antoni Vilaseca, MD
LBA105 - Results From SunRISe-1 in Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer Receiving TAR-200 Monotherapy
Presented By: Andrea Necchi, MD
|
|
|
|
|
|
|
|
|
|
| Presidential 2 10:30 AM - 12:15 PM EST
|
|
|
|
|
LBA6 - EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma
Presented By: Thomas Powles, MBBS, MRCP, MD
|
|
|
|
|
LBA7 - Nivolumab plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone for Previously Untreated Unresectable or Metastatic Urothelial Carcinoma: Results from the Phase 3 CheckMate 901 Trial
Presented By: Michiel S. Van der Heijden, MD, Ph.D.
|
|
|
|
|
|
|
| Presidential 3 10:30 AM - 12:15 PM EST
|
|
|
|
|
LBA13 - Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer (PSMAfore)
Presented By: Oliver Sartor, MD
|
|
|
|
|
Invited Discussant LBA13
Presented By: Christopher Sweeney, MBBS
|
|
|
|
|
|
|
1784P - Prostate-Specific Antigen Outcomes with Darolutamide, Androgen-Deprivation Therapy and Docetaxel in Patients with High- and Low-Volume Metastatic Hormone-Sensitive Prostate Cancer in ARASENS
Presented By: Fred Saad, MD, FRCS
|
|
|
|
|
1813P - Phase 1/2 Trial of Oral EPI-7386 in Combination with Enzalutamide Compared to Enz Alone in Metastatic Castration-Resistant Prostate Cancer Subjects: Current Phase 1 results
Presented By: Andrew L. Laccetti, MD, MS
|
|
|
|
|
1823P - The Impact of Baseline PSMA PET/CT vs. CT on Outcomes of Radium-223 Therapy in mCRPC Patients
Presented By: Dianne Bosch, MD
|
|
|
|
|
1826P - Lutetium-177-PSMA in Pre- and Post-Taxane mCRPC Setting - Results from a Phase II Clinical Trial
Presented By: Emilio Giunta, MD
|
|
|
|
|
1827P - Real-World Overall Survival with Enzalutamide and Abiraterone Acetate in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
Presented By: Daniel George, MD
|
|
|
|
|
1838P - Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Lymphopenia in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617: VISION Post Hoc Analysis
Presented By: Xiao X. Wei, MD, MAS
|
|
|
|
|
1841TiP - Darolutamide plus Androgen-Deprivation Therapy in Patients with High-Risk Biochemical Recurrence of Prostate Cancer: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ARASTEP)
Presented By: Alicia K. Morgans, MD, MPH
|
|
|
|
|
1912TiP - STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib and Nivolumab in Non-Clear Cell Renal Cell Carcinoma
Presented By: Sumanta Pal, MD, FASCO
|
|
|
|
|
|
|
|
